P.033 Detection of Myelin Oligodendrocyte Glycoprotein Immunoglobulin G (MOG-IgG) by live and fixed cell-based assays.

Kumar, P; Cruz, A; Sodhi, H; Waters, P; Victor Mgbachi, V; Woodhall, M; Mousavi, A; Oger, J; Aziz, T; Frykman, H

Background: MOG-IgG is associated with non-MS demyelinating disease of the optic nerves, spinal cord and brain. Specificity has been issue so we validated the live and fixed MOG-IgG CBAs against the Oxford Autoimmune Neurology Diagnostic Laboratory (OANG) live CBA as a comparator with high specificity. Methods: At BC Neuroimmunology lab (BCNI), 54 MOG-IgG serum samples previously positive by live-CBA at OANG and BCNI were blindly tested by commercial fixed CBA. All 54 MOG IgG positives came from MOG-IgG positive patients. In addition, 256 samples from healthy people and other neurolgic disease were tested. Results: The live MOG-IgG CBA performed at BCNI was 100% concordant (54/54) with OANG live CBA. In contrast, only 49/54 samples were found seropositive by the commercial fixed CBA. The BCNI live-CBA identified 3/256 control samples as positive while 6/256 controls were positive on the fixed commercial CBA. On this cohort the live CBA is 100% sensitive, 98.8% specific and has PPV of 95%. The commercial fixed MOG test is 91% sensitive, 97.6% specific and has PPV of 87.5%. Conclusions: BCNI live MOG-IgG CBAs are in 100% agreement with MOG-IgG. Three positive results in non-MOGAD associated clinical phenotype require further investigation. These data confirm the superiority of the live MOG CBA.

MYELIN oligodendrocyte glycoprotein; OPTIC nerve diseases; IMMUNOGLOBULIN G; DEMYELINATION; SPINAL cord

Canadian Journal of Neurological Sciences, 2022, Vol 49, Issue S1, pS16

0317-1671

Academic Journal

10.1017/cjn.2022.135